226 results about "Ischemic stroke" patented technology

The invention provides a multi-modal cerebral arterial thrombosis medical image segmentation method, device and equipment, and the method comprises the steps: extracting the independent features of different modal medical images through combining a ViT encoder branch and a CNN encoder branch which are finely adjusted by a hybrid expert as a multi-modal image double-branch coding network; further integrating complementary information of different modes by using a mode missing adaptive fusion network, and performing global-local information interaction between CNN features and ViT features by using an encoder branch interaction network, so that specific features and cross-mode invariant features of different available modes can be decoupled under the condition of mode missing; and meanwhile, the advantages of different types of features are fully utilized, and the value information of the multi-modal image features is deeply mined, so that accurate multi-modal cerebral arterial thrombosis medical image segmentation and imaging are realized, and the method is high in reliability, good in accuracy and good in practicability.

Provided are an siRNA which inhibits plasma coagulation factor XI gene expression, a pharmaceutical composition containing the siRNA, a conjugate, a reagent kit, and a use of the siRNA, the pharmaceutical composition thereof and the conjugate in preparing a drug used for treating and / or preventing thrombotic diseases and ischemic strokes.

The invention discloses a nasal delivery multistage targeting bionic nano drug delivery system as well as a preparation method and application of the nasal delivery multistage targeting bionic nano drug delivery system. According to the drug delivery system, a black phosphorus nanosheet with an active oxygen scavenging effect is used as an inner core carrier, a neuroprotective agent fingolimod hydrochloride FTY720 and polydimethyldiguanide PolyMet are loaded, and a microcolloid cell membrane and a mitochondrial membrane are modified on the surface of the preparation; the nano drug delivery system is applied to treatment of cerebral arterial thrombosis reperfusion injury, can overcome the blood brain barrier, can quickly enter the brain through nasal administration, realizes efficient delivery of drugs, remarkably reduces the cerebral infarction area, reduces the brain inflammation level, protects nerve cells, greatly relieves cerebral arterial thrombosis reperfusion injury, and has application prospects.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

The invention provides an ischemic stroke auxiliary diagnosis system based on a peripheral blood T cell single cell transcriptome and application thereof, and the auxiliary diagnosis system comprises a peripheral blood mononuclear cell acquisition module, a single cell RNA sequencing module, a data processing module, a data analysis module and a result discrimination module. With a coding gene of a protein molecule significantly related to the occurrence of ischemic stroke as a target gene, a data processing module obtains the expression level of the target gene in each T cell; the data analysis module obtains a risk score of each T cell of the subject by using a built-in single cell risk scoring model, and weights the risk scores of all the T cells through distributed perception identification to obtain an individual risk score of the subject; and the result judgment module is used for classifying the subjects into ischemic stroke negative and ischemic stroke positive according to the individualized risk scores of the subjects. The auxiliary diagnosis system disclosed by the invention is high in ischemic stroke discrimination capability, and high in sensitivity and specificity.

The invention discloses application of eugenin in preparation of a medicine for treating cerebral arterial thrombosis, and belongs to the technical field of medicines. An in-vivo middle cerebral artery occlusion model is adopted, after reperfusion is conducted for 24 h, the cerebral infarction volume and movement coordination function defect of a mouse are detected to evaluate the treatment effect of eugenin, and activation of microglial cells and survival of neuronal cells are observed through immunofluorescence to clarify the action way of eugenin. Pharmacological activity shows that eugenin can obviously reduce the cerebral infarction volume of a model mouse, improve pathological damage of cells and promote recovery of a motion coordination function, and the action way of eugenin is to promote survival of neuronal cells and inhibit activation of microglial cells. Research results indicate that eugenin has the effect of resisting cerebral arterial thrombosis and can be used as a candidate medicine for developing the cerebral arterial thrombosis resisting medicine.

The scheme provides a kind of engineered exosome double drug delivery system loaded with ergosterol and its preparation method and application, belongs to the field of nanomaterials and nanobiomedicine, based on the innovative ROS-responsive nanomaterial CHPG design, load the active ingredient ergosterol to play the role of treatment and repair, which realizes the blood-brain barrier penetration and precise drug release in lesion area through targeted functional modification;It is wrapped in the nasal mucosa-derived stem cell exosome to form a drug delivery system Exo@Erg-CHPG-M, which combines the natural biological characteristics of exosome and the precise targeting advantage of nanomicelle, significantly improves the drug delivery efficiency, in vitro and animal model verification show that, the system can improve the neurological impairment and brain tissue injury after ischemic stroke by synergistically regulating inflammation and neural repair pathways, the scheme provides a new technical scheme for the precise treatment of central nervous system diseases such as cerebral stroke.

The present invention relates to a biomarker composition for diagnosing stroke or post-stroke neurological damage, for diagnosing the severity of stroke or post-stroke neurological damage, and for predicting stroke prognosis, and the like. Using an ischemic stroke mouse disease model, a tissue damage analysis and a behavioral analysis were performed, and the mRNA level expression was confirmed, and as a result, Prox1 or Dcx could be selected as a biomarker. In addition, it was confirmed that the expression of Prox1 or Dcx increased as the severity of stroke or post-stroke neurological damage was higher, and thus the present invention is expected to be useful for diagnosing stroke or post-stroke neurological damage, for diagnosing the severity of stroke or post-stroke neurological damage, and for predicting stroke prognosis.

The invention belongs to the field of in-vitro diagnostic reagents, and particularly relates to application of a reagent for detecting biomarkers in serum in preparation of a cerebral arterial thrombosis diagnostic kit. The invention determines that the concentrations of lactic acid, isoleucine, fumaric acid, ketoglutaric acid, hypoxanthine, tyrosine, histidine and inosine in serum of a cerebral arterial thrombosis (IS) patient are significantly related to major atherosclerosis (LAA) and minor artery occlusion (SAO), so that the concentrations of the biomarkers can be used as a basis for diagnosing IS and distinguishing LAA and SAO.

The present application relates to the technical field of medicine, and provides a kind of haena polysaccharide and its preparation method and application and target endogenous coagulation pathway anticoagulant and / or antithrombotic drug.The haena polysaccharide provided by the present application is fucosylated chondroitin sulfate polysaccharide, the weight average molecular weight is 9-13 million, the molar ratio of glucuronic acid, N-acetylglucosamine and fucose is 1:0.8-1.2:0.5-0.8, and the mass percentage content of sulfate group is 25-40%.The haena polysaccharide provided by the present application can target endogenous coagulation pathway terminal rate-limiting enzyme (iFXase), and has no obvious effect on coagulation factors in other coagulation pathways, realizes the effect of anticoagulation and non-hemorrhage, and can be widely applied in acute and recovery period treatment of ischemic stroke, solves the safety problem of using anticoagulant and antithrombotic drug for clinical ischemic stroke patients, and opens up a new field of research and development of target endogenous coagulation pathway rate-limiting enzyme anticoagulant drug.

The invention relates to a structural network-genetic map biological network model for predicting ischemic stroke and a construction method thereof, and the method comprises the steps: extracting and calculating seven multi-scale morphological features and pairwise Pearson correlation coefficients among the features from T1 weighted imaging data and diffusion tensor imaging data; constructing a 308 * 308 morphological similarity network matrix and a brain network module for identifying ischemic stroke neural dysfunction; 1782 sampling points are extracted from the Airy human brain map, and each sampling point comprises expression data of 10185 genes; the method comprises the following steps: mapping space coordinates of AHBA sampling points to a cortex package of a Desikan-Killiany map, carrying out normalization processing to output 308 * 10185 brain region gene-by-gene expression matrixes, and constructing a structural network-gene map biological network model for predicting ischemic stroke by adopting a partial least square regression method and a bootstrap method. Compared with the prior art, the model determines the specific molecular mechanism related to the phenotypic structure change of ischemic stroke injury, and the stroke occurrence probability is predicted according to the specific molecular mechanism.

The present application relates to a kind of hyperbranched polymer, nano preparation and its preparation method and application, belong to functional medical material and nanotechnology field.The hyperbranched polymer of the present application can be broken in ROS environment Release dihydrolipoic acid, play the role of antioxidant, be reduced to lipoic acid in vivo, and then play its role as coenzyme, participate in mitochondrial tricarboxylic acid cycle, restore mitochondrial function, thereby play the role of antioxidant and play the role of treating ischemic stroke.The nano preparation provided by the present application can be quickly distributed to brain in a short time, temporarily increase the paracellular permeability of BBB by inhibiting the expression of multi-drug resistance protein P-gp and ATP-dependent drug efflux protein on BBB, and the process of opening BBB by borneol is physiological and reversible, without destroying the structural integrity of blood-brain barrier.

The application relates to an IL-10 high-expression mesenchymal stem cell secretion component, a preparation method thereof and application thereof in prevention and treatment of ischemic cerebral stroke, and belongs to the technical field of cerebral stroke treatment. In order to solve the problems existing in the current stem cell clinical medication and administration method for ischemic cerebral stroke, the application provides a specially treated mesenchymal stem cell secretion component (hMSC-M), the secretion component is an IL-10 high-expression stem cell secretion component obtained by using a basic culture medium containing human IFN-gamma protein and TNF-alpha simulation peptide to induce human mesenchymal cells after expansion, and then harvesting culture and repeatedly freezing and thawing. The application finds that the hMSC-M has a significant effect on prevention and treatment of ischemic cerebral stroke through animal experiments, thereby opening up a new drug use for stem cell application, laying a foundation for developing high-efficiency related drugs for preventing and treating ischemic cerebral stroke injury, and providing a new application scheme and thought.

The invention discloses mizoribine for treating cerebral arterial thrombosis. It is found for the first time that mizoribine can reduce the cerebral apoplexy infarction area, inhibit immune cell infiltration of the brain, relieve inflammation of the cerebral parenchyma stroke part, improve damage to the nervous system of the stroke part and promote recovery of the damaged nerve function.

The invention describes catheter systems and methods for accessing the brain during endovascular / neurointervention procedures in the treatment of ischemic stroke. More specifically, a multi-axial catheter system and kit is described that improves the process of accessing a carotid artery particularly in patients having a tortuous aortic arch and thereafter improves the process of gaining access to the brain to enable the insertion of aspiration and / or the deployment clot retrieval devices. In addition, methods of utilizing these systems are described.

The invention relates to a mesenchymal stem cell-nano knapsack system, preparation thereof and application of the mesenchymal stem cell-nano knapsack system in treatment of cerebral arterial thrombosis. The invention constructs an engineered mesenchymal stem cell-thrombin responsive nano knapsack for sequential targeted delivery of rtPA, antioxidant active molecules and MSCs for ischemic stroke treatment. In a sequential delivery mode, firstly, a thrombus site is targeted, the thrombin is responded to release rtPA for thrombolysis, brain blood supply is recovered, and the rtPA thrombolysis efficiency is improved. The antioxidant active molecules are entrapped on the erythrocyte membrane bionic nanoparticles, are loaded on the surfaces of the MSCs in a knapsack form, penetrate through BBB and tend to damage ischemic penumbra and release the antioxidant active molecules by means of central transport and inflammatory homing effects of the MSCs, on one hand, oxidative stress is inhibited, a microenvironment beneficial to activity maintenance is provided for the MSCs, and on the other hand, the antioxidant active molecules are released; and meanwhile, the medicine cooperates with MSCs to play a role in protecting injured nerve and blood vessel units, so that the treatment effect on cerebral arterial thrombosis is improved.

The present invention relates to pharmaceutical compositions and methods for treating ischemic stroke in humans, using a tetrafluorobenzyl derivative of formula (I) or a pharmaceutically acceptable salt thereof conjointly with a thrombolytic drug, endovascular thrombectomy, or both (e.g., endovascular thrombectomy and a thrombolytic drug). Administration of a tetrafluorobenzyl derivative of formula (I) or its pharmaceutically acceptable salt can reduce reperfusion injury and other adverse events in patients conjointly receiving a thrombolytic drug, endovascular thrombectomy, or endovascular thrombectomy with a thrombolytic drug.

The application discloses application of a marker in preparation of a product for diagnosing or assisting in diagnosing ischemic cerebral stroke, the marker being CLDN7 and / or PPM1B, and it is found through verification of clinical samples that the marker has high diagnostic efficiency on ischemic cerebral stroke, can be used as a biomarker for diagnosing and differentiating ischemic cerebral stroke, and has the advantages of high accuracy, good specificity, high sensitivity and the like, provides a brand-new thought and strategy for early diagnosis of ischemic cerebral stroke in the field, and has good clinical application value.

The invention relates to the technical field of medicines, in particular to application of DP-b99 and a derivative thereof in preparation of a medicine for treating cerebral ischemia mechanical thrombus extraction reperfusion injury. On the basis of mechanical thrombus extraction and reperfusion of cerebral ischemia, DP-b99 is combined to reduce mechanical thrombus extraction and reperfusion injury of cerebral arterial thrombosis, so that the inflammation level of brain tissues can be reduced, the volume of cerebral infarction can be reduced, the injury of the brain tissues can be effectively reduced, and the treatment effect is remarkable.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.

The invention relates to the technical field of medicines, in particular to application of benzbromarone in preparation of antithrombotic drugs. The research finds that benzbromarone clinically used for treating hyperuricemia can be combined with HSP47 on platelets to inhibit the interaction between the HSP47 and collagen so as to reduce platelet activation and thrombosis, which prompts that benzbromarone is an HSP47 inhibitor with an anti-platelet effect; benzbromarone has the effects of inhibiting mouse common carotid artery thrombosis and relieving cerebral ischemia reperfusion injury. Experiments finally confirm that benzbromarone can inhibit formation of common carotid artery thrombosis, does not affect the blood coagulation function, is low in cytotoxicity, has the drug effect similar to that of aspirin and clopidogrel which are commonly used at present, and can become an effective and safe therapeutic drug for cerebral arterial thrombosis.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 neuron cells and hCMEC / D3 brain microvascular endothelial cells injured by oxygen-glucose deprivation (OGD) induction, and can resist the injury of PC12 cells induced by corticosterone (CORT) and MPP + , and effectively inhibit the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, and can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve and vascular units.

The application belongs to the technical field of pharmaceutical chemistry, and particularly relates to a PSD-95 PDZ2 peptidomimetic inhibitor and application thereof. A series of compounds are designed and synthesized by taking a tetrapeptide ETAV as a template, a structure-activity relationship of the compounds with PSD-95 PDZ2 is systematically studied, and an optimal compound 32-2, i.e., the PSD-95 PDZ2 peptidomimetic inhibitor, is screened, a structural formula of which is shown as formula (I), the PSD-95 PDZ2 peptidomimetic inhibitor has very excellent plasma stability, and exhibits significant neuroprotective activity in in-vivo and in-vitro biological activity evaluation, significantly reduces cerebral infarction caused by cerebral ischemia-reperfusion injury, and can be used for preparing a drug for treating ischemic stroke. (I).

This invention discloses the application of substances that inhibit Trx1 nitration in the preparation of drugs for treating Trx1 nitration-related diseases. This invention reveals for the first time that nitration modification of tyrosine residue 49 (Y49) of the Trx1 protein is a key pathological step in diseases such as ischemic stroke and myocardial ischemia-reperfusion injury. Inhibiting nitration at this site can effectively restore Trx1 reductase activity, enhance the binding of Trx1 to ASK1, and block the downstream ASK1-p38 / JNK apoptosis signaling pathway, thereby exerting a therapeutic effect. This invention provides a novel treatment strategy for Trx1 nitration-related diseases.

The invention provides a metal manganese complex, a metal manganese nano platform, a preparation method and application, and belongs to the technical field of chemical synthesis and biomedicine. The structural formula of the manganese complex is shown as a formula I. The method comprises the following steps: dropwise adding a MnCl2 aqueous solution into a THF solution containing Ce6, quickly stirring, carrying out ultrasonic treatment, and sufficiently aging to obtain preliminary Mn-Ce6NPs; and the Mn-Ce6NPs obtained in the first step is subjected to dialysis and centrifugation, and the metal manganese complex Mn-Ce6NPs is obtained. The nanoparticles have excellent chemiluminescence performance, and can specifically recognize the position of a suppository block. The prepared nanoparticles have a photodynamic and photo-thermal combined thrombolysis effect, and have an anti-oxidation function after thrombolysis, so that the purpose of treating ischemic stroke is achieved.

The invention discloses application of a PLAU signal channel inhibitor in treating ischemic cerebral apoplexy and a pharmaceutical composition, and belongs to the field of biological medicine. The PLAU signal channel inhibitor inhibits the activation of an NF-kappa B channel and reduces the generation of inflammatory factors (IL-1beta, IL-6 and TNF-alpha) by inhibiting the expression of PLAU protein in cells. Experiments prove that the PLAU signal channel inhibitor can remarkably improve related pathological indexes of ischemic cerebral apoplexy, the cerebral infarction area is reduced by more than or equal to 30%, the vascular endothelial cell activity is improved by more than or equal to 25%, the inflammatory factor level is reduced by more than or equal to 40%, and the protective effect on cerebral ischemia reperfusion injury is superior to the overall effect of a traditional Chinese medicine compound. The invention provides a clear mechanism basis for targeted therapy of ischemic cerebral apoplexy.

The invention discloses a biomarker combination for auxiliary diagnosis of lung adenocarcinoma and risk early warning of lung adenocarcinoma complicated with ischemic stroke and application of the biomarker combination. The biomarker combination comprises an SLC25A39 gene, an NME4 gene, an LDHA gene and an SLC7A5 gene. Reagents for detecting the expression levels of the SLC25A39 gene, the NME4 gene, the LDHA gene and the SLC7A5 gene in the biomarker combination can be applied to preparation of products for auxiliary diagnosis of the lung adenocarcinoma and risk early warning of the lung adenocarcinoma complicated with ischemic stroke, and the effect of one-detection dual-energy is achieved.

The invention belongs to the technical field of cell culture, and discloses a cell culture device for an experiment for treating cerebral ischemia stroke based on long non-coding RNA, the cell culture device comprises an incubator, a cross-shaped partition plate is fixedly connected in the incubator, a culture mechanism is arranged in the incubator, the culture mechanism comprises four stabilizing assemblies and a temperature control assembly, and the temperature control assembly is connected with the cross-shaped partition plate. The stabilizing assembly and the temperature control assembly are matched for use, the stabilizing assembly comprises sliding rails, the sliding rails are fixedly connected to the interior of the incubator, and sliding blocks are symmetrically and slidably connected to the interiors of the two sliding rails. By arranging the culture mechanism, stable, independent and environment-controllable parallel culture is carried out on a plurality of experimental samples in the same culture box, the culture dish can be stably clamped and fixed to prevent accidental overturning, and the culture dish has the partitioned independent temperature control capability; therefore, stable, reliable and flexible hardware support is provided for related frontier biomedical research.

The invention belongs to the technical field of biology, and particularly relates to application of Lnc-PLBD1-AS1 and MCEMP1 as prognosis biomarkers of acute ischemic stroke. According to the application disclosed by the invention, it is found that the expression levels of baseline Lnc-PLBD1-AS1 and MCEMP1 of people who are dead within one year after an acute cerebral arterial thrombosis patient is attacked are obviously higher than those of survival patients, and the Lnc-PLBD1-AS1 and MCEMP1 have good prediction efficiency for evaluating the risk of death of the acute cerebral arterial thrombosis patient within one year after the acute cerebral arterial thrombosis patient is attacked by the acute cerebral arterial thrombosis patient is attacked by the acute cerebral arterial thrombosis patient; the expression levels of the baselines Lnc-PLBD1-AS1 and MCEMP1 of people suffering from the adverse function outcome (death or severe disability) of acute cerebral arterial thrombosis patients after attack for 3 months are obviously higher than those of other patients, and the Lnc-PLBD1-AS1 and MCEMP1 have good prediction efficiency for evaluating the risk of the adverse function outcome of the acute cerebral arterial thrombosis patients after attack for 3 months.

This invention, based on the screening and identification of environmental exocomics and metabolomics biomarkers associated with ischemic stroke, discloses an ischemic stroke risk assessment model and model construction method that integrates environmental exocomics and metabolomics biomarkers, improving the comprehensiveness, accuracy, and convenience of prediction. This invention systematically evaluates the association between exposure to mixed organic pollutants and the risk of ischemic stroke, identifying key pollutants; quantifies the impact of pollutant mixtures on the systemic metabolic network and stroke risk, revealing the mediating role of metabolic pathway disorders in pollutant-induced stroke risk; explores the potential of incorporating pollutant exposure information into clinical prediction models to improve the efficacy of ischemic stroke risk stratification, ultimately providing systematic multi-omics evidence for the causal relationship between environmental pollution and ischemic stroke, and offering new technical tools for precision disease prevention.